Invention Grant
- Patent Title: Subcutaneous administration of ADAMTS13
-
Application No.: US17525759Application Date: 2021-11-12
-
Publication No.: US11779635B2Publication Date: 2023-10-10
- Inventor: Alexandra Nathalie Kopic , Werner Hoellriegl , Barbara Plaimauer , Hanspeter Rottensteiner , Eva-Maria Muchitsch
- Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Applicant Address: JP Osaka
- Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
- Current Assignee Address: JP Osaka
- Agency: Troutman Pepper Hamilton Sanders LLP
- The original application number of the division: US14210167 2014.03.13
- Main IPC: A61K38/48
- IPC: A61K38/48 ; C12N9/64 ; A61K9/00 ; A61K9/19
Abstract:
This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
Public/Granted literature
- US20220080032A1 SUBCUTANEOUS ADMINISTRATION OF ADAMTS13 Public/Granted day:2022-03-17
Information query
IPC分类:
